Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Ocumension Therapeutics / Equity Capital Markets

Ocumension Therapeutics, a leading ophthalmic pharmaceutical platform company with a focus on first-in-class or best-in-class ophthalmic therapies, aims to raise up to USD 300 million via a Hong Kong listing.While the majority of the Chapter 18A IPOs has a focus on innovative oncology drugs, this company is unique in the sense that it has a long list of ophthalmology drugs in the late stage of development. The company's assets cover major eye diseases (cataracts, glaucoma, age-related macular degeneration (AMD), dry eye syndrome and allergic conjunctivitis) except diabetic retinopathy (DR).Looking at its product pipeline, we had an impression that the company's key assets are mainly licensed in products that have not proven to generate big revenue in the overseas market though there is improvement over the current standard of care. Despite a short history of operation, the company has a broad spectrum of ophthalmological indications and is backed by reputable investors. The management is experienced and has track record of drug development in the relevant field.

Ocumension Therapeutics, a leading ophthalmic pharmaceutical platform company with a focus on first-in-class or best-in-class ophthalmic therapies, aims to raise up to USD 300 million via a Hong Kong listing.While the majority of the Chapter 18A IPOs has a focus on innovative oncology drugs, this company is unique in the sense that it has a long list of ophthalmology drugs in the late stage of development. The company's assets cover major eye diseases (cataracts, glaucoma, age-related macular degeneration (AMD), dry eye syndrome and allergic conjunctivitis) except diabetic retinopathy (DR).Looking at its product pipeline, we had an impression that the company's key assets are mainly licensed in products that have not proven to generate big revenue in the overseas market though there is improvement over the current standard of care. Despite a short history of operation, the company has a broad spectrum of ophthalmological indications and is backed by reputable investors. The management is experienced and has track record of drug development in the relevant field. 

Ocumension (欧康维视) Pre-IPO: All Ready for a Great Listing Except a Block Buster

China

Ocumension Therapeutics operates as a pharmaceutical company. The Company focuses on identifying, developing, and commercializing ophthalmic therapies. Ocumension Therapeutics serves customers in the United States and China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ocumension Therapeutics (1477 HK)

Ocumension (欧康维视) Pre-IPO: All Ready for a Great Listing Except a Block Buster

Ocumension Therapeutics, a leading ophthalmic pharmaceutical platform company with a focus on first-in-class or best-in-class ophthalmic therapies,...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)